WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of 20.50 billion. The enterprise value is 20.03 billion.
Market Cap | 20.50B |
Enterprise Value | 20.03B |
Important Dates
The last earnings date was Wednesday, August 20, 2025.
Earnings Date | Aug 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | -2.55% |
Shares Change (QoQ) | -0.30% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 3.54B |
Valuation Ratios
The trailing PE ratio is 35.00 and the forward PE ratio is 27.65.
PE Ratio | 35.00 |
Forward PE | 27.65 |
PS Ratio | 7.32 |
PB Ratio | 2.99 |
P/TBV Ratio | 3.42 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 34.20 |
EV / Sales | 7.09 |
EV / EBITDA | 21.11 |
EV / EBIT | 25.89 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.
Current Ratio | 2.88 |
Quick Ratio | 2.40 |
Debt / Equity | 0.10 |
Debt / EBITDA | 0.76 |
Debt / FCF | n/a |
Interest Coverage | 31.72 |
Financial Efficiency
Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.64%.
Return on Equity (ROE) | 10.50% |
Return on Assets (ROA) | 5.89% |
Return on Invested Capital (ROIC) | 6.64% |
Return on Capital Employed (ROCE) | 10.57% |
Revenue Per Employee | 223,025 |
Profits Per Employee | 46,667 |
Employee Count | 12,575 |
Asset Turnover | 0.34 |
Inventory Turnover | 6.36 |
Taxes
In the past 12 months, WuXi Biologics has paid 172.04 million in taxes.
Income Tax | 172.04M |
Effective Tax Rate | 20.03% |
Stock Price Statistics
The stock price has increased by +245.74% in the last 52 weeks. The beta is 0.42, so WuXi Biologics's price volatility has been lower than the market average.
Beta (5Y) | 0.42 |
52-Week Price Change | +245.74% |
50-Day Moving Average | 8.13 |
200-Day Moving Average | 6.23 |
Relative Strength Index (RSI) | 67.55 |
Average Volume (20 Days) | 77,650 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of 2.80 billion and earned 585.76 million in profits. Earnings per share was 0.14.
Revenue | 2.80B |
Gross Profit | 1.19B |
Operating Income | 766.36M |
Pretax Income | 859.06M |
Net Income | 585.76M |
EBITDA | 939.69M |
EBIT | 766.36M |
Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 1.75 billion in cash and 712.90 million in debt, giving a net cash position of 1.04 billion.
Cash & Cash Equivalents | 1.75B |
Total Debt | 712.90M |
Net Cash | 1.04B |
Net Cash Per Share | n/a |
Equity (Book Value) | 6.85B |
Book Value Per Share | 1.54 |
Working Capital | 2.23B |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.
Gross Margin | 42.65% |
Operating Margin | 27.38% |
Pretax Margin | 30.69% |
Profit Margin | 20.92% |
EBITDA Margin | 33.57% |
EBIT Margin | 27.38% |
FCF Margin | n/a |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 2.55% |
Shareholder Yield | n/a |
Earnings Yield | 2.86% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
The last stock split was on December 10, 2020. It was a forward split with a ratio of 3.
Last Split Date | Dec 10, 2020 |
Split Type | Forward |
Split Ratio | 3 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 5 |